Autoantibodies in long COVID: A mechanistic foothold in a heterogeneous disease.
Where this comes from
- Record sourced from PubMed, PMID 42208496.
- Also identified by DOI 10.1016/j.cell.2026.04.044.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Long COVID is a heterogeneous, multi-system disease that poses challenges for patients, health systems, and economies. Two papers in Cell and Cell Reports Medicine from independent groups suggest that autoantibodies in a subset of long COVID patients can directly drive symptoms such as pain, fatigue, or neurocognitive problems.
Medical subject headings
- COVID-19
- Autoantibodies